Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature

Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypogl...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2022-04, Vol.13, p.860614-860614
Main Authors: Oziel-Taieb, Sandrine, Maniry-Quellier, Jemima, Chanez, Brice, Poizat, Flora, Ewald, Jacques, Niccoli, Patricia
Format: Article
Language:English
Subjects:
Endocrinology
Female
Humans
Hypoglycemia - drug therapy
Hypoglycemia - etiology
Insulinoma - complications
Insulinoma - drug therapy
Insulinoma - pathology
malignant insulinoma
Middle Aged
neuroendocrine tumor
Pancreatic Neoplasms - complications
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - pathology
pancreatic neuroendocrine cancer
pasireotide
refractory hypoglycemia
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.860614